Goldman Sachs Resumes Biogen (BIIB) at Conviction Buy on Upcoming Drug Launches
Tweet Send to a Friend
Goldman Sachs resumes coverage on Biogen (NASDAQ: BIIB) with a Conviction Buy List rating and $178 price target.
"Biogen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
"Biogen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
